https://www.selleckchem.com/pr....oducts/gf109203x.htm
Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 11 ratio to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in gr
Like
Comment
Share
